Trial Profile
Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Vadadustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Akebia Therapeutics
- 16 Apr 2018 Results published in the Nephrology Dialysis Transplantation
- 07 Nov 2015 Primary endpoint has been met (Change in Week 8 Hemoglobin), according to results published in a company media release.
- 07 Nov 2015 Results published in the Media Release